Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Theravance Biopharma, Inc is a biotechnology business based in the US. Theravance Biopharma shares (TBPH) are listed on the NASDAQ and all prices are listed in US Dollars. Theravance Biopharma employs 316 staff and has a trailing 12-month revenue of around USD$82.6 million.
|Latest market close||USD$18.04|
|52-week range||USD$14.48 - USD$31.54|
|50-day moving average||USD$18.0691|
|200-day moving average||USD$19.7048|
|Wall St. target price||USD$31.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.05|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||N/A|
|1 month (2020-12-15)||N/A|
|3 months (2020-10-15)||N/A|
|6 months (2020-07-15)||N/A|
|1 year (2020-01-15)||N/A|
|2 years (2019-01-15)||N/A|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||N/A|
|Revenue TTM||USD$82.6 million|
|Gross profit TTM||USD$-145,834,000|
|Return on assets TTM||-38.1%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 3.5 million Theravance Biopharma shares held short by investors – that's known as Theravance Biopharma's "short interest". This figure is 0.4% up from 3.5 million last month.
There are a few different ways that this level of interest in shorting Theravance Biopharma shares can be evaluated.
Theravance Biopharma's "short interest ratio" (SIR) is the quantity of Theravance Biopharma shares currently shorted divided by the average quantity of Theravance Biopharma shares traded daily (recently around 374344.82029598). Theravance Biopharma's SIR currently stands at 9.46. In other words for every 100,000 Theravance Biopharma shares traded daily on the market, roughly 9460 shares are currently held short.
However Theravance Biopharma's short interest can also be evaluated against the total number of Theravance Biopharma shares, or, against the total number of tradable Theravance Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Theravance Biopharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Theravance Biopharma shares in existence, roughly 60 shares are currently held short) or 0.1405% of the tradable shares (for every 100,000 tradable Theravance Biopharma shares, roughly 141 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Theravance Biopharma.
Find out more about how you can short Theravance Biopharma stock.
We're not expecting Theravance Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Theravance Biopharma's shares have ranged in value from as little as $14.48 up to $31.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theravance Biopharma's is 0.9554. This would suggest that Theravance Biopharma's shares are less volatile than average (for this exchange).
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.